Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 6,226Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Otezla

02 3Otezla

PharmaCompass

01

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2020 Revenue in Millions : 2,195

2019 Revenue in Millions : 178

Growth (%) : 1,133

blank

02

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2021 Revenue in Millions : 2,249

2020 Revenue in Millions : 2,195

Growth (%) : 2

blank

03

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2022 Revenue in Millions : 2,288

2021 Revenue in Millions : 2,249

Growth (%) : 2

blank

04

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2023 Revenue in Millions : 2,188

2022 Revenue in Millions : 2,288

Growth (%) : -4

blank

05

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2019 Revenue in Millions : 178

2018 Revenue in Millions : 0

Growth (%) : N/A

blank

06

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Skin Disorder

Currency : USD

2015 Revenue in Millions : 70

2014 Revenue in Millions : 472

Growth (%) : 574%

blank

07

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2017 Revenue in Millions : 1,279

2016 Revenue in Millions : 1,017

Growth (%) : 26

blank

08

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2016 Revenue in Millions : 1,017

2015 Revenue in Millions : 472

Growth (%) : 115

blank

09

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2018 Revenue in Millions : 1,608

2017 Revenue in Millions : 1,279

Growth (%) : 26%

blank

10

Brand Name : Otezla

Apremilast

arrow
CPhI India 2024
Not Confirmed

Brand Name : Otezla

arrow
CPhI India 2024
Not Confirmed

Apremilast

Main Therapeutic Indication : Dermatology

Currency : USD

2019 Revenue in Millions : 1,429

2018 Revenue in Millions : 1,608

Growth (%) : -11

blank